Company
NRXP +3.81%NRx Pharmaceuticals, Inc.
Market Cap: $134.8 Million
USD as of Aug 2, 2026
$NRXP +3.81% $NRXP United States Healthcare Biotechnology US Healthcare US BiotechnologyNRx Pharmaceuticals, Inc. Market Capitalization Over Time
View HistoryEvolution of NRx Pharmaceuticals, Inc. market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Financials
| Last Financial Reports Date | None |
| Revenue TTM | $None |
| EBITDA | $None |
| Gross Profit TTM | $None |
| Profit Margin | % |
| Operating Margin | % |
| Quarterly Revenue Growth | % |
Stocks & Indexes
NRx Pharmaceuticals, Inc. main stocks and indexes inclusions.
$NRXPNASDAQ Composite